Biological E. Limited (Be), A Hyderabad-Based Pharmaceutical And Vaccine Company, Announced That Its 14-Valent Paediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine Pcv14) Against S. Pneumoniae Infection Received Approval From The Drugs Controller General Of India (Dcgi) For Manufacture And Commercialisation In India. Pcv14 May Be Administered To Infants 6, 10 And 14 Weeks Of Age In 3 Doses. Streptococcus Pneumoniae Infection Remains One Of The Leading Causes Of Death Among Children Under The Age Of Five In India And In Developing Countries. Be'S Pcv14 Vaccine Will Help Prevent Invasive Pneumococcal Infection And Save Millions Of Lives Worldwide. Be
